<DOC>
	<DOCNO>NCT02854072</DOCNO>
	<brief_summary>To assess treatment GV1001 concurrent Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone locally advanced metastatic pancreatic cancer patient .</brief_summary>
	<brief_title>A Phase III Study Assess Efficacy Safety GV1001-Gem/Cap v Gem/Cap Pancreatic Cancer Patients</brief_title>
	<detailed_description>This study design phase III , prospective , randomize , open-label , multicenter clinical trial compare GV1001 concurrent Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone treat locally advance metastatic pancreatic cancer patient . Patients treated disease progression subject follow-up death . Patients randomize equally two arm : 1 . Gemcitabine Capecitabine 2 . GV1001+ Gemcitabine Capecitabine</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Age ≥ 19 year 2 . Histologically cytologically proven pancreatic ductal adenocarcinoma carcinoma undifferentiated carcinoma pancreas . 3 . Locally advanced metastatic disease preclude curative surgical resection patient relapse follow previously resect pancreatic cancer . 4 . Contrast enhance CT scan thorax , abdomen pelvis within 28 day ( maximum 32 day ) prior commence treatment . 5 . Unidimensionally measurable disease ( CT scan ) accordance RECIST guideline . 6 . ECOG performance status 0 , 1 2 . 7 . Adequate organ function determine follow laboratory value : Platelets ≥100 x 10^9 /L WBC ≥ 3 x 10^9 /L ANC ≥1.5 x 10^9 /L Serum total bilirubin ≤ 2.0 mg/dL CCr ( Cockcroft &amp; Gault ) &gt; 50 mL/min 8 . Life expectancy ≥ 90 day 9 . Fully inform write consent give . 1 . Brain metastasis meningeal carcinomatosis . 2 . Clinically significant serious disease organ system disease currently control present therapy . 3 . Previous chemotherapy locally advance metastatic disease . Previously adjuvant chemotherapy resect pancreatic cancer permit provide chemotherapy complete 12 month previously . 4 . Radiotherapy within last 8 week prior start study treatment . 5 . Concurrent malignancy invasive cancer diagnose within past 5 year except adequately treat basal cell carcinoma skin , situ carcinoma uterine cervix resect pancreatic cancer . 6 . Medication might affect immunocompetence e.g . chronic treatment long term steroid immunosuppressant unrelated condition . Patients eligible receive short term steroid palliation cancer relate symptom . 7 . Administration medicine clinical trial within 8 week registration . 8 . Pregnancy breast feed . 9 . Uncontrolled angina pectoris . 10 . Known malabsorption syndrome . 11 . Patients know hypersensitivity investigational product patient dihydropyrimidine dehydrogenase ( DPD ) deficiency . 12 . All men woman reproductive potential , unless use least two contraceptive precaution , one must condom . 13 . Investigator 's judgment participation study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>GV1001</keyword>
</DOC>